ClinicalTrials.gg
CompletedNCT01299285Updated Jun 8, 2017Results posted

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

A Phase 1 interventional study of LY3009104 in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-08.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a single dose study of radiolabeled [14C]-LY3009104 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY3009104. This study requires minimum of 7 days and maximum of 22 days stay. This study is for research purposes only and is not intended to treat any medical condition.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Absorption
  • Distribution
  • Metabolism
  • Excretion
  • Mass balance
  • Metabolic profile
  • Radiolabeled study
  • 14C
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy males, as determined by medical history and physical examination
  • Will either be sterile or, if sexually active, agree to use a reliable method of from check-in until 3 months after the end of the study
  • (BMI) between 19 and 30 kilogram/square meter (kg/m²)
  • Experience on average 1 to 2 bowel movements per day
  • Clinical laboratory test results within the normal reference range for the clinical research unit (CRU) or, results with acceptable deviations which are judged to be not by the investigator
  • Normal blood pressure and heart rate (sitting) as determined by the investigator
  • Venous access sufficient to allow blood sampling
  • Are reliable and willing to make themselves available for the duration of the study, and are willing to abide by the CRU policies and procedures, and study restrictions
  • Have given written approved by Lilly and the Institutional Review Board (IRB) governing the CRU

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, have completed or discontinued, a clinical trial involving an product or are concurrently enrolled in any other type of medical research judged not to be scientifically, or medically compatible with this study
  • Have known allergies to LY3009104, related compounds, or any components of the formulation
  • Have previously received the investigational product in this study, have completed or withdrawn from this study or any other study investigating LY3009104
  • History or presence of an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, is
  • Current or recent history (\<30 days prior to Screening and/or \<45 days prior to Check-in) of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
  • An (ANC) less than 2000 cells/microliter. For abnormal values a single repeat will be allowed
  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Show evidence of significant active neuropsychiatric disease and in particular evidence of significant medical or psychiatric illness within the past 12 months
  • Have known substance dependence or abuse within 6 months prior to the study (according to the , Fourth Edition [DSM-IV] diagnosis), or regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Show evidence of and/or positive hepatitis C antibody
  • Evidence (active or surface antigen positive [HBsAg+]) or hepatitis B core antibody positive, hepatitis B surface antibody negative (HBcAb+, HBsAb-)
  • Use of prescription medication; over-the-counter medication; or herbal preparations containing St. John's Wort, kava, garlic, ginger, gingko biloba, or guarana within 14 days prior to admission
  • Consumption of grapefruit or grapefruit-containing foods or juices within 7 days prior to dosing or at any time during the study
  • Have an average weekly alcohol intake that exceeds 15 units per week, or are unwilling to stop alcohol consumption for the duration of the study (1 unit = 12 oz or 360 milliliter (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
  • Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine restrictions (no caffeine 48 hours prior to admission until the end of study
  • Use of tobacco or nicotine-replacement products within the 6 months prior to study entry or at any time during the study
  • Have donated blood of more than 500 mL within the last month
  • Have participated in a 14C-study within the last 6 months prior to Check-in for this study. The total exposure from this study and the previous study must be within the Code of Federal Regulations (CFR) recommended levels considered safe (per 21 CFR 361.1), for example less than 5,000 millirem (mrem)/year whole body annual exposure
  • Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    LY3009104

    Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104

    Drug: LY3009104

Interventions

  • Administered orally

    Also known as: Baricitinib

06

What researchers measure

Primary outcomes

  1. Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces

    Time frame: Baseline up to 120 hours

Secondary outcomes

  1. Plasma Pharmacokinetics: LY3009104 Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]

    Time frame: Baseline up to 48 hours

  2. Plasma Pharmacokinetics: Radioactivity Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]

    Time frame: Baseline up to 48 hours

  3. Plasma Pharmacokinetics: Maximum Observed LY3009104 Concentration (Cmax)

    Time frame: Baseline up to 48 hours

  4. Plasma Pharmacokinetics: Maximum Observed Radioactivity Concentration (Cmax)

    Time frame: Baseline up to 48 hours

  5. Plasma Pharmacokinetics: LY3009104 and Radioactivity Time to Maximum Observed Concentration (Tmax)

    Time frame: Baseline up to 48 hours

  6. Percentage of Dose of LY3009104 and LY3009104 Metabolites in Urine

    Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the urine are reported. Only those metabolites that were detectable in the urine are included in the report.

    Time frame: Baseline up to 48 hours

  7. Percentage of Dose of LY3009104 and LY3009104 Metabolites in Feces

    Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the feces are reported. Only those metabolites that were detectable in the feces are included in the report.

    Time frame: Baseline up to 72 hours

  8. Percentage of Total Radioactivity of LY3009104 and LY3009104 Metabolites in Plasma

    Time frame: Baseline up to 24 hours

07

Results

Posted Apr 21, 2017

Participant flow

Participant flow — Overall Study
MilestoneLY3009104 (Baricitinib)
Started6
Completed6
Not completed0

Outcome measures

PrimaryPercentage of the Total Radioactive Dose Administered Excreted From Urine and Feces
Time frame:
Baseline up to 120 hours
Reported as:
Mean · percentage of total radioactivity
Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces
percentage of total radioactivityLY3009104
Urine75.2 ± 6.74
Feces19.9 ± 4.92
SecondaryPlasma Pharmacokinetics: LY3009104 Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]
Time frame:
Baseline up to 48 hours
Reported as:
Geometric mean · hour*nanomoles/liter(h*nmol/L)
Plasma Pharmacokinetics: LY3009104 Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]
hour*nanomoles/liter(h*nmol/L)LY3009104
Plasma Pharmacokinetics: LY3009104 Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]1570 ± 28
SecondaryPlasma Pharmacokinetics: Radioactivity Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]
Time frame:
Baseline up to 48 hours
Reported as:
Geometric mean · hour*nanomole-equivalents/kilogram
Plasma Pharmacokinetics: Radioactivity Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]
hour*nanomole-equivalents/kilogramLY3009104
Plasma Pharmacokinetics: Radioactivity Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]1530 ± 31
SecondaryPlasma Pharmacokinetics: Maximum Observed LY3009104 Concentration (Cmax)
Time frame:
Baseline up to 48 hours
Reported as:
Geometric mean · nanomoles/liter (nmol/L)
Plasma Pharmacokinetics: Maximum Observed LY3009104 Concentration (Cmax)
nanomoles/liter (nmol/L)LY3009104
Plasma Pharmacokinetics: Maximum Observed LY3009104 Concentration (Cmax)227 ± 36
SecondaryPlasma Pharmacokinetics: Maximum Observed Radioactivity Concentration (Cmax)
Time frame:
Baseline up to 48 hours
Reported as:
Geometric mean · nanomole-equivalents/milliliter
Plasma Pharmacokinetics: Maximum Observed Radioactivity Concentration (Cmax)
nanomole-equivalents/milliliterLY3009104
Plasma Pharmacokinetics: Maximum Observed Radioactivity Concentration (Cmax)231 ± 35
SecondaryPlasma Pharmacokinetics: LY3009104 and Radioactivity Time to Maximum Observed Concentration (Tmax)
Time frame:
Baseline up to 48 hours
Reported as:
Median · hour
Plasma Pharmacokinetics: LY3009104 and Radioactivity Time to Maximum Observed Concentration (Tmax)
hourLY3009104
LY30091041.00 (1.00 to 2.00)
Radioactivity1.00 (1.00 to 2.00)
SecondaryPercentage of Dose of LY3009104 and LY3009104 Metabolites in Urine

Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the urine are reported. Only those metabolites that were detectable in the urine are included in the report.

Time frame:
Baseline up to 48 hours
Reported as:
Number · percentage of dose
Percentage of Dose of LY3009104 and LY3009104 Metabolites in Urine
percentage of doseLY3009104
LY300910468.5
Metabolite M30.9
Metabolite M101.0
Metabolite M223.2
SecondaryPercentage of Dose of LY3009104 and LY3009104 Metabolites in Feces

Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the feces are reported. Only those metabolites that were detectable in the feces are included in the report.

Time frame:
Baseline up to 72 hours
Reported as:
Number · percentage of dose
Percentage of Dose of LY3009104 and LY3009104 Metabolites in Feces
percentage of doseLY3009104
LY300910414.8
Metabolite M120.9
SecondaryPercentage of Total Radioactivity of LY3009104 and LY3009104 Metabolites in Plasma
Time frame:
Baseline up to 24 hours
Reported as:
Number · percentage of total radioactivity
Percentage of Total Radioactivity of LY3009104 and LY3009104 Metabolites in Plasma
percentage of total radioactivityLY3009104LY3009104 Metabolites
1 hour92.30
2 hour94.50
4 hour97.00
8 hour91.20
24 hour00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY3009104—0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventLY3009104
Ocular hyperaemiaEye disorders1/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)LY3009104
Mean36.7 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)LY3009104
Female0
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)LY3009104
Asian1
White5
Region of Enrollment
Region of Enrollment(participants)LY3009104
United States6
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madison, Wisconsin, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 6 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2011
First posted
Feb 18, 2011
Start
Feb 2011
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Apr 21, 2017
Last update
Jun 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01299285
Responsible party
Sponsor
First posted
Feb 18, 2011
Start date
Feb 2011
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Apr 21, 2017
Last update
Jun 8, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559, Mon - Fri, 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion